Abstract:Background Tumor necrosis factor receptor type 2 (TNFR2) is primarily expressed by CD4 + FoxP3 + regulatory T cells (Tregs), especially those present in tumor microenvironment. There is compelling evidence that TNFR2 plays a crucial role in the activation, expansion, and phenotypic stability of Tregs and promotes tumor immune evasion. Understanding of epigenetic regulation of TNFR2 expression in Tregs may help device a novel strategy in cancer immunotherapy. Methods MiR-125b-5p-overexpressing or knockdown murine CD4 T cells and Tregs were constructed, and the effect of miR-125b-5p on Tregs proliferation, suppressive function and TNFR2 expression were examined. In vivo antitumor efficacy of Ago-125b-5p (miR-125b-5p agomir) was evaluated in MC38 tumor bearing mice, and tumor-infiltrating Tregs and CD8 + cytotoxic T lymphocytes (CTLs) were analyzed. RNA-seq analysis was applied to reveal the genes and signaling pathways regulated by miR-125b-5p in Tregs. Results In this study, we found that TNFR2 was a direct target of miR-125b-5p. Overexpression of miR-125b-5p decreased the proportion of Tregs and their expression of TNFR2 and consequently inhibited its proliferation and suppressive function by regulating the metabolism-related signaling pathways. Moreover, in colon cancer bearing mice, the administration of Ago-125b-5p markedly inhibited the tumor growth, which was associated with reduction of Tregs and increase of IFNγ + CD8 + T cells in tumor environment. Furthermore, in human colon adenocarcinoma patients, we verified that miR-125b-5p expression was downregulated, and low levels of miR-125b-5p were associated with poor prognosis. Interestingly, the expression of miR-125b-5p and TNFR2 were negatively correlated. Conclusions Our study for the first time found that the expression of TNFR2 by Tregs was regulated by miR-125b-5p. Our results showed that miR-125b-5p had the capacity to inhibit the expression of TNFR2 and immunosuppressive activity of Tregs and consequently enhanced the antitumor efficacy. This property of miR-125b-5p may be therapeutically harnessed in the treatment of human cancers.

Tumor-secreted Mir-214 Delivered on T Cells to Promote Tumor Growth

Tumor-secreted Mir-214 Induces Regulatory T Cells: a Major Link Between Immune Evasion and Tumor Growth

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

Tumor-secreted microRNAs act as intercellular communication mediators to manipulate the host immune system

Mir-182 Targeting Reprograms Tumor-Associated Macrophages and Limits Breast Cancer Progression

Tumor-promoting Properties of Mir-8084 in Breast Cancer Through Enhancing Proliferation, Suppressing Apoptosis and Inducing Epithelial–mesenchymal Transition

TGF-β-Regulated MicroRNAs and Their Function in Cancer Biology.

Pancreatic Cancer Derived Exosomes Regulate the Expression of TLR4 in Dendritic Cells Via Mir-203

Secreted microRNAs from tumor cells can suppress immune function.

TGF-β-associated Mir-27A Inhibits Dendritic Cell-Mediated Differentiation of Th1 and Th17 Cells by TAB3, P38 MAPK, MAP2K4 and MAP2K7

Cancer-derived Circulating MicroRNAs Promote Tumor Angiogenesis by Entering Dendritic Cells to Degrade Highly Complementary MicroRNAs.

MiR-15a/16 Deficiency Enhances Anti-Tumor Immunity of Glioma-Infiltrating CD8+ T Cells Through Targeting Mtor.

MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2

Regulatory T cells in tumor immunity

Precise Spatiotemporal Interruption of Regulatory T-cell-Mediated CD8(+) T-cell Suppression Leads to Tumor Immunity

Mir-221/222 Promote Cancer Stem-Like Cell Properties and Tumor Growth of Breast Cancer Via Targeting PTEN and Sustained Akt/NF-κB/COX-2 Activation.

Intravenous injection of tumor extracellular vesicles suppresses tumor growth by reducing the regulatory T cell phenotype

Exosomal Mirna-107 Induces Myeloid-Derived Suppressor Cell Expansion in Gastric Cancer

Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development

Synergistic effect of radiotherapy and dendritic-cell-based immunotherapy via miR-15b-5p regulation in a colon carcinoma mouse model

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.